Axial spondyloarthritis, a chronic inflammatory disease primarily affecting the spine, can extend its reach beyond the back, impacting other joints – most notably, the hips. New research highlights the frequency and significance of hip involvement in individuals with axial spondyloarthritis, revealing a link between hip disease and increased disease severity. Understanding this connection is crucial for optimizing patient care and improving long-term outcomes.
While axial spondyloarthritis is often recognized for its spinal manifestations, a substantial proportion of patients also experience inflammation in the hips. A recent retrospective analysis conducted at a rheumatology outpatient clinic in Rabat, Morocco, sheds light on the prevalence of this extraspinal involvement. The study, examining data from 137 patients with confirmed ankylosing spondylitis between 2019 and 2023, found that radiographic hip involvement – defined as hip pain linked to inflammatory activity and supported by imaging – affected 13.90% of the cohort. This finding underscores the importance of considering hip health in the comprehensive management of axial spondyloarthritis.
Defining Hip Involvement and Patient Characteristics
Researchers defined hip involvement using the Bath Ankylosing Spondylitis Radiology Hip Index (BASRI), requiring a score of at least 2 to indicate radiographic changes consistent with inflammatory disease. The analysis revealed that hip involvement presented unilaterally in nine patients and bilaterally in ten, demonstrating that the condition can affect one or both hips. Further investigation revealed specific patient characteristics associated with a higher likelihood of hip involvement. Notably, men were more frequently affected, and the risk increased with longer disease duration.
The study also identified a correlation between hip involvement and the presence of uveitis, an inflammatory eye condition. This suggests that individuals experiencing hip inflammation may be part of a subgroup with more pronounced and widespread disease activity. Kaplan Meier estimates indicated that the risk of hip involvement rose over time, with 18.6% of male patients affected after 10 years of disease and nearly half – 48.8% – impacted after 20 years of living with the condition. This highlights the importance of long-term monitoring for hip involvement in male patients with axial spondyloarthritis.
Severity and Disease Activity
Patients exhibiting hip involvement demonstrated higher scores on measures of disease activity and structural damage. Specifically, they had elevated Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) values, indicating greater symptomatic severity. Their modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) values were higher, reflecting a greater structural burden of disease. These findings collectively suggest that hip involvement is not merely a coincidental finding but rather a marker of more aggressive and damaging disease.
The authors of the study noted that the prevalence of hip involvement observed in their outpatient cohort was somewhat lower than figures reported in studies conducted at university hospital settings. This difference may reflect variations in patient populations and referral patterns. However, the consistent association between hip involvement and increased disease severity remains a significant finding.
Implications for Patient Care
The findings emphasize the need for clinicians to proactively assess hip health in patients with axial spondyloarthritis, particularly those with longer disease duration and male patients. Early detection and management of hip inflammation may aid mitigate its impact on functional outcomes and overall quality of life. Further research is needed to determine the optimal strategies for preventing and treating hip involvement in this patient population.
As our understanding of axial spondyloarthritis evolves, it’s becoming increasingly clear that a holistic approach to care – one that considers both spinal and extraspinal manifestations – is essential. Continued investigation into the underlying mechanisms driving hip involvement will pave the way for more targeted and effective therapies.
Disclaimer: This article provides informational content and should not be considered medical advice. Please consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
Have you or someone you know been affected by hip involvement in axial spondyloarthritis? Share your experiences in the comments below. Please also share this article with others who may find it helpful.
